Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nezam Afdhal

Showing results (51-60 of 71) with videos related to

Pageof 8
Sort By:
Hepatology (Baltimore, Md.)|October 24, 2009
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonrespondersVinod K Rustgi, William M Lee, Eric Lawitz, et al.
Hepatology (Baltimore, Md.)|May 13, 2015
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trialsSaleh A Alqahtani, Nezam Afdhal, Stefan Zeuzem, et al.
Lancet (London, England)|December 14, 2012
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up studyPatrick Marcellin, Edward Gane, Maria Buti, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 21, 2017
Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral TherapyIra M Jacobson, Mary K Washington, Maria Buti, et al.
Hepatology (Baltimore, Md.)|September 27, 2007
Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trialIra M Jacobson, Robert S Brown, Bradley Freilich, et al.
Hepatology (Baltimore, Md.)|February 15, 2019
Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2)Markus Peck-Radosavljevic, Krzysztof Simon, Angelo Iacobellis, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 30, 2019
Three Years of Progress Toward Achieving Hepatitis C Elimination in the Country of Georgia, April 2015-March 2018Tengiz Tsertsvadze, Amiran Gamkrelidze, Nikoloz Chkhartishvili, et al.
Open Forum Infectious Diseases|February 17, 2018
Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 StudiesJason Grebely, Jordan J Feld, David Wyles, et al.
Hepatology (Baltimore, Md.)|November 9, 2015
Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 dataJulius M Wilder, Lennox J Jeffers, Natarajan Ravendhran, et al.
Lancet (London, England)|March 19, 2013
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trialKris V Kowdley, Eric Lawitz, Israel Crespo, et al.
Pageof 8

Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
Hepatology (Baltimore, Md.)|October 24, 2009
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonrespondersVinod K Rustgi, William M Lee, Eric Lawitz, et al.
Hepatology (Baltimore, Md.)|May 13, 2015
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trialsSaleh A Alqahtani, Nezam Afdhal, Stefan Zeuzem, et al.
Lancet (London, England)|December 14, 2012
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up studyPatrick Marcellin, Edward Gane, Maria Buti, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 21, 2017
Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral TherapyIra M Jacobson, Mary K Washington, Maria Buti, et al.
Hepatology (Baltimore, Md.)|September 27, 2007
Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trialIra M Jacobson, Robert S Brown, Bradley Freilich, et al.
Hepatology (Baltimore, Md.)|February 15, 2019
Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2)Markus Peck-Radosavljevic, Krzysztof Simon, Angelo Iacobellis, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 30, 2019
Three Years of Progress Toward Achieving Hepatitis C Elimination in the Country of Georgia, April 2015-March 2018Tengiz Tsertsvadze, Amiran Gamkrelidze, Nikoloz Chkhartishvili, et al.
Open Forum Infectious Diseases|February 17, 2018
Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 StudiesJason Grebely, Jordan J Feld, David Wyles, et al.
Hepatology (Baltimore, Md.)|November 9, 2015
Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 dataJulius M Wilder, Lennox J Jeffers, Natarajan Ravendhran, et al.
Lancet (London, England)|March 19, 2013
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trialKris V Kowdley, Eric Lawitz, Israel Crespo, et al.
Pageof 8